Prnewsnow Reach the World NOW

↑ Grab this Headline Animator

HoustonBased Endothelix Receives FDA Approval for New Cardiovascular...



Endothelix has announced that its non-invasive VENDYS technology, which utilizes a simple blood pressure cuff and fingertip probes to monitor vascular reactivity (http://www.endothelix.com/) in response to an arm-cuff occlusion, which serves as a vascular stress test.



The company's FDA approval follows multiple clinical trials conducted in major cities and supported by a $1 million award from the Texas Emerging Technology Fund, an initiative from Governor Rick Perry's economic reform committee. "This benchmark represents proven success by Endothelix and a rewarding investment for Texas," Governor Rick Perry said. "The Emerging Technology Fund allows Texas to invest in innovative companies which are key to driving competition, advancement and diversification in our state's robust economy and the global marketplace."



According to well-known cardiovascular (http://www.endothelix.com/) with a non-invasive, non-imaging procedure that is simple, inexpensive and user friendly.



Automated cuff occlusion implemented by the VENDYS device causes a significant drop in fingertip temperature followed by temperature rebound after cuff release. The speed and magnitude of temperature recovery is a measure of vascular reactivity (http://www.endothelix.com/) risk factors and greater coronary plaque build-up than those with higher fingertip thermal reactivity.



"I am impressed by the data from the Endothelix clinical trials," says Dr. Mathew Budoff, Professor of Medicine at UCLA and Director of Cardiovascular Imaging at the Los Angeles Biomed Institute. "VENDYS technology is indeed very promising."



Cardiovascular disease (CVD) is not only America's number one killer (more than one million deaths each year), but also the most expensive disease (more than $350 billion per year). According to the American Heart Association, three out of four heart attack ().



Current methods for CVD screening include traditional blood tests for measurement of risk factors (such as cholesterol) or advanced atherosclerosis imaging tests (such as CAT scans and MRIs). While traditional risk factors are statistical predictors of future CVD, they do not measure the state of an individual's vascular health. In addition, advanced imaging modalities have significant cost or radiation barriers, and therefore cannot be used repeatedly (weekly or monthly).



"Endothelix is striving to bring a comprehensive non-invasive, non-imaging cardiovascular risk assessment solution to doctors' offices that is simple, inexpensive, and operator independent," says Dr. Naghavi, Founder and President of Endothelix.



By incorporating a comprehensive risk assessment platform into primary care, Endothelix intends to enable family physicians to practice as preventive cardiologists.



"Endothelix is creating a groundbreaking approach which will provide a revolutionary and innovative, low-cost way to address the cardiac market," said Walter Ulrich, President and CEO of the Houston Technology Center (HTC).



Endothelix has been assisted by HTC since 2005. The company is also affiliated with BioHouston, a local organization that supports Houston-based life science companies.



"We are excited about the prospects of Endothelix as an emerging, leading cardiovascular company based in Houston," said Jacqueline Northcut, President and CEO of BioHouston.



About Endothelix


Endothelix is a Delaware corporation based in Houston, Texas and formed in December 2003. The company is positioned as the first to incorporate non-invasive, non-imaging micro and macro vascular (endothelial -dependent and -independent) function monitoring technologies into the existing risk factor assessment to help physicians more accurately monitor their patients' cardiovascular health, and to use appropriate therapies for the prevention and treatment heart of attack and stroke.



Endothelix has established research collaborations with University of Houston, Texas A&M University, University of Texas - Austin, Baylor College of Medicine, Lenox Hill Hospital, Columbia University, Harbor UCLA Medical Center, Cedars-Sinai Medical Center and MD Anderson Cancer Center. Endothelix's Scientific Advisory Board includes world-renowned cardiovascular specialists including Daniel Berman MD, Matthew Budoff MD, Erling Falk MD, PhD, Craig Hartley PhD, Harvey Hecht MD, Ioannis Kakadiaris PhD, Obdulia Ley PhD, Roxana Mehran MD, Ralph Metcalfe PhD, Khurram Nasir MD, Arshed Quyyumi MD, John Rumberger MD, PhD, and Hirofumi Tanaka PhD. Visit www.biohouston.org for more information.






Prnewsnow Reach the World NOW

↑ Grab this Headline Animator

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Poker | Tournament Winnings | tournament winnings excess |




Last 1000 Articles Submitted XML FEEDS FOR ORGANIZED NEWS